are there clinically significant differences among the third generation egfr inhibitors?
Published 8 years ago • 36 plays • Length 3:28Download video MP4
Download video MP3
Similar videos
-
3:25
are there significant differences among the 1st and 2nd generation egfr tkis?
-
4:44
are there clinically significant differences among the second generation alk inhibitors?
-
2:22
are there distinctions among currently available oral egfr inhibitors?
-
3:28
should third generation egfr inhibitors be used before or after progression?
-
2:19
differences among specific egfr mutations
-
3:15
does the specific egfr mutation matter when choosing an oral egfr inhibitor?
-
1:01
dr. philip bonomi: gefitinib and later generations of egfr inhibitors
-
31:21
covid-19 symposium: cellular responses to sars-cov-2 | dr. michael betts
-
6:02
egfr mutation and cancer
-
19:57
gracecast-015_cancer-101_david djang interview on pet scans
-
1:24:49
advancing high-quality evidence-based supportive care - ysn webinar
-
3:07
third generation egfr tkis for acquired resistance
-
2:54
are there clinical differences among immune checkpoint inhibitors treating lung cancer?
-
5:09
should a third generation egfr inhibitor be first line therapy for egfr mutation-positive nsclc?
-
1:59
what is egfr and the egfr mutation?
-
12:58
egfr inhibitor therapy in second line
-
6:29
case based panel discussion nsclc – does a positive her2 mutation effect treatment decisions?
-
2:30
acquired resistance to osimertinib in egfr nsclc - 2022 program: targeted therapies forum - english
-
6:00
case based panel discussions - egfr mutation & met - treatment decisions, level of met amplification
-
1:26
first line treatment of egfr mutation-positive nsclc
-
4:22
what is egfr in lung cancer? - 2022 program: targeted therapies forum
-
26:27
novel egfr inhibitors in the setting of acquired resistance